Navigation Links
Study Shows Intradigm's RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
Date:4/14/2008

therapeutics."

The findings presented today support data from several other in vivo models, including xenograft models of different cancers, which have demonstrated the efficacy of the RNAi NPX delivery technology.

ABOUT THE RNAi NANOPLEX DELIVERY TECHNOLOGY

To address the issue of effective and targeted delivery of RNAi therapeutics, Intradigm has developed and in-licensed an extensive intellectual property portfolio around its proprietary RNAi Nanoplex (NPX) delivery technology. The RNAi NPX delivery technology is a modular, multi-component delivery vector that carries active siRNA molecules in its core with the flexibility to attach a Polyethylene Glycol (PEG) layer and/or a targeting ligand to the polymer-siRNA NPX to improve circulation half life and achieve selective distribution to the target tissue. At the core of the RNAi NPX delivery technology is Intradigm's proprietary peptide-based biodegradable polymer known as PolyTran(TM). PolyTran enables safe systemic delivery of the siRNAs. Additionally, this platform is unique in its ability to offer tissue specific targeting of siRNA through the attachment of specific ligands directed to target cell receptors. An additional key strength of the RNAi NPX delivery technology is its ability to incorporate multiple siRNAs in a single drug product. These multi-targeted therapeutics can simultaneously silence several mRNAs that represent parallel or synergistic elements of the same disease pathway resulting in a more comprehensive and/or novel therapeutic potential.

Recent technology licensing agreements with institutions such as the University of Massachusetts Medical School and the Massachusetts Institute of Technology have enhanced Intradigm's existing intellectual property portfolio and provided the company with the rights and know-how to leverage a broad family of polymers and polymer structures, as well as next generation siRNA structures, in connection with its RNAi NPX delivery techn
'/>"/>

SOURCE Intradigm Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months
2. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
3. Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea
4. Antipodean Pharmaceuticals Announces Completion of Phase 2 Study of Lead Compound MitoQ(R)
5. Three Dimensional Visualization of Right Ventricle Provides Important Information for Treatment of Patients with Tetralogy of Fallot, According to a Study in The American Journal of Cardiology
6. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
7. UltraShape(R) Non-Invasive Fat Reduction and Body Contouring Clinical Study Results Featured at American Society for Laser Medicine and Surgery Meeting
8. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
9. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
10. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
11. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/27/2008)...ec. 23 Warner Chilcott L...of its subsidiaries and Mayne Pharma International...., have filed lawsuits against each of Mutual Phar...euticals Inc. ("Mylan") and Impax Laboratories, In...ct of New Jersey for infringement of Mayne,s U.S. ...
(Date:12/17/2008)...n development and validation of non-animal alterna...17 MatTek Corporation today announ...ESAC) endorsed the scientific validity of the Modi...ember meeting. ESAC concluded that the Modified E... for the prediction of skin irritating and non-irr...
(Date:12/17/2008)... PEAK Surgical, Inc., a medical,de...ction system based on a,proprietary technology, a...stration (FDA) has granted the company 510(k) clea...tting and coagulation of soft tissue during,plast... gynecologic,orthopedic, arthroscopic, spinal an...
(Date:12/17/2008)...e, December 17 NicOx,S....tive results of a,pre-specified pooled analysis o...e 301, 302 and 303 pivotal phase 3 studies for nap...ificant reduction in systolic and diastolic blood,...g bid over the whole 13 week,period (p<0.001 f...
Breaking Medicine Technology:Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 2Warner Chilcott Files Lawsuits for Infringement of DORYX(R) Patent 3EpiDerm's Skin Irritation Test Fully Validated in European Union 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 2NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 3NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 4NicOx' Naproxcinod Shows Robust Blood Pressure Results in Phase 3 Pooled Analysis 5June GEOSPHERE media highlights 3472 1June GEOSPHERE media highlights 3472 2June GEOSPHERE media highlights 3472 3June GEOSPHERE media highlights 3472 4Inflammation depression and antidepressant response 3A Common mechanisms 20582 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 1OHSU Cancer Institute researchers find many stomach cancer patients are not gertting best therapy 20578 2Certain Tests in ERs Raise Cancer Risk for Some 20575 1Certain Tests in ERs Raise Cancer Risk for Some 20575 2Certain Tests in ERs Raise Cancer Risk for Some 20575 3Certain Tests in ERs Raise Cancer Risk for Some 20575 4
(Date:1/8/2009)..., First Announced Acquisition in 2009 Continues G... IPC The Hospitalist Com...ospitalist physician group practice company, annou...actice of Midwest Acute Care Consultants, Inc. (MA...ents continued expansion in the St. Louis market, ...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-Asia/ -- ...HDX" or "the Company"), a leading independent Amer...services in the People,s Republic,of China, today...BS Greater,China Conference, to be held in Shangh... Greater China Conference will be held at the Pudo...
(Date:1/8/2009)..., ROCKVILLE, Md., Jan. 8 /PRNewswire-USNewswire/ ...ctives, advice and guidance on drugs, biological p...althcare Research and Quality,s Centers for Educat...lly sponsored network of more than a dozen leading...mer Health Advisory Information Network ( CHAIN ) ...
(Date:1/8/2009)..., FRAZER, Pa., Jan. 8 ...that Frank Baldino, Jr., Ph.D., Chairman and CEO w...nce, to be held on January 13, 2009 in San Francis...p.m. Eastern Time). The presentation will be webca...ompany,s website. , , The webcast will be arch...
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:Chindex International Inc. Announces Participation in the 2009 UBS Greater China Conference 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 2Health News:Cephalon, Inc. to Present at the J.P. Morgan Healthcare Conference 3
...ic and geographic data of the H5N1 avian flu virus...//They found that multiple strains of the virus or... they identified many of the migration routes thro...y and internationally. By knowing where H5N1 stra...
...ons of brain function in the field of conducting t...reparing to move when a traffic light turns green.... of psychology at the Georgia Institute of Technol... they conducted MRI brain scans of their subjects ...
...daily may have the potential to reverse impairment... to a first-of-its-kind study published in the Jou...d in the study was rich in flavanols, naturally-oc...ocoa prior to their destruction during the typical...
...netic roots of the most common form of amyotrophic...e newly identified 34 unique variations in the hum...ALS. The 34 so-called single nucleotide polymorp...e genes predisposing people to the noninherited fo...
Other Medicine News:Health News:UCI Scientists Reconstruct Migration of Avian Flu Virus 2Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 2Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 3Health News:New Study Suggests Special Cocoa may Lead to Sustained Improvement in Blood Vessel Function 4Health News:Gene Hunters at Johns Hopkins Close In On Lou Gehrig's Disease 2
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
...ce laboratory and a worldwide leader in innovative...an extensive test menu of highly complex and uniqu.... Owned by the University of Utah, ARUP Laboratori... university teaching hospitals and children's hosp...
Medicine Products: